Sveriges mest populära poddar
Research To Practice | Oncology Videos
Hälsa och motionMedicin

Breast Cancer | Oncology Today with Dr Neil Love: Recent Updates in HER2-Low Breast Cancer

36 min•7 juli 2022

Featuring an interview with Dr Adam Brufsky, including the following topics:

  • Trastuzumab deruxtecan (T-DXd) for HER2-low breast cancer; recently presented findings from the DESTINY-BREAST04 trial (0:00)
  • Impact of heterogeneous disease on the detection of HER2-low expression in patients with breast cancer (7:48)
  • Case: A woman with low-volume, asymptomatic and nonvisceral ER-positive, HER2-low breast cancer (13:16)
  • Case: A woman with high-volume, symptomatic and visceral HER2-low breast cancer; treating ER-negative, HER2-low disease (18:44)
  • Toxicities associated with T-DXd (25:25)
  • Ongoing trials evaluating T-DXd in earlier lines of therapy (31:28)

CME information and select publications

Fler avsnitt av Research To Practice | Oncology Videos

Visa alla avsnitt av Research To Practice | Oncology Videos
Oral SERDs for Breast Cancer | Erica Mayer, MD, MPH, FASCO
•29 min
Oral SERDs for Breast Cancer | Aditya Bardia, MD, MPH
•28 min
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
•57 min
EGFR-Mutant Non-Small Cell Lung Cancer | Suresh S Ramalingam, MD
•26 min
EGFR-Mutant Non-Small Cell Lung Cancer | Helena Yu, MD
•30 min
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
•17 min
Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances
•58 min
Prostate Cancer | Scott T Tagawa, MD, MS
•25 min
Prostate Cancer | Andrew J Armstrong, MD, ScM
•24 min
Menin Inhibitors in Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
•59 min

Research To Practice | Oncology Videos med Dr Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.